Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 28:12:16-25.
doi: 10.2174/1874357901812010016. eCollection 2018.

Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals

Ivan Schietroma  1 , Giuseppe Corano Scheri  1 , Claudia Pinacchio  1 , Maura Statzu  2 , Arnolfo Petruzziello  3 , Vincenzo Vullo  1
Affiliations
Review

Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals

Ivan Schietroma et al. Open Virol J. .

Abstract

Introduction: Globally, between 64 and 103 million people are chronically infected with Hepatitis C virus (HCV), with more than 4.6 million people in the United States and is associated with more than 15.000 deaths annually. Chronic infection can result in cirrhosis and hepatocellular carcinoma.

Explanation: Epidemiological studies have indicated that persistent infection with hepatitis C virus (HCV) is a major risk for the development of hepatocellular carcinoma (HCC), mainly through chronic inflammation, cell deaths, and proliferation. Despite the new direct-acting antiviral drugs (DAA's) being able to clear the HCV, HCC recurrence rate in these patients is still observed.

Conclusion: In this review we highlighted some aspects that could be involved in the onset of HCV-induced HCC such as immune system, viral factors and host genetics factors.Moreover, we focused on some of the last reports about the effects of DAA's on the HCV clearance and their potential implications in HCC recurrence.

Keywords: Chronic infection; DAA’s; HCC; HCV; Immunity; Viral factors.

PubMed Disclaimer

References

    1. Chacko S., Samanta S. “Hepatocellular carcinoma: A life-threatening disease”. Biomed. Pharmacother. 2016;84:1679–1688. doi: 10.1016/j.biopha.2016.10.078. - DOI - PubMed
    1. Elia G., Fallahi P. Hepatocellular carcinoma and CXCR3 chemokines: A narrative review. Clin. Ter. 2017;168(1):e37–e41. - PubMed
    1. Balogh J., Victor D., III, Asham E.H., Burroughs S.G., Boktour M., Saharia A., Li X., Ghobrial R.M., Monsour H.P., Jr Hepatocellular carcinoma: A review. J Hepatocell Carcinoma. 2016;3:41–53. doi: 10.2147/JHC.S61146. - DOI - PMC - PubMed
    1. Nawaz R., Zahid S., Idrees M., Rafique S., Shahid M., Ahad A., Amin I., Almas I., Afzal S. HCV-induced regulatory alterations of IL-1β, IL-6, TNF-α, and IFN-ϒ operative, leading liver en-route to non-alcoholic steatohepatitis. Inflamm. Res. 2017;66(6):477–486. doi: 10.1007/s00011-017-1029-3. - DOI - PubMed
    1. de Oliveria Andrade L.J., D’Oliveira A., Melo R.C., De Souza E.C., Costa Silva C.A., Paraná R. Association between hepatitis C and hepatocellular carcinoma. J. Glob. Infect. Dis. 2009;1(1):33–37. doi: 10.4103/0974-777X.52979. - DOI - PMC - PubMed

LinkOut - more resources